USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE RENAL TRANSPLANTATION IN HLA-SENSITIZED PATIENTS

摘要

Methods for desensitization of patients in need of organ transplant are provided. Human leukocyte antigen-sensitized patients awaiting incompatible kidney transplant have been treated with clazakizumab to show reduced or eliminated levels of donor-specific antibodies and an improved transplant rate. Clazakizumab and variants are provided for use in various embodiments of the methods. In some embodiments, clazakizumab, or its variants, is administered simultaneously or sequentially with intravenous immunoglobulin.